← Issue №17/
week of Oct 25, 2026/
the whole section, in full
Colorectal, in full.
All 4 Colorectal papers in this issue,
as full cards, ranked by clinical utility. The issue page carries the strongest few;
this is the section, whole.
Actionability = is there something to do. Prevalence = how much of a general GI practice it touches. Stakes = how consequential the decision is. Evidence strength = how far the study design and the result support the action. Novelty = how likely you are not already doing it.
Colorectalrct · n=400 · Oct 24, 2026 · Lancet · IF 98.4
Clinical takeawayConsider the 14-day trifluridine-tipiracil plus bevacizumab schedule for refractory metastatic colorectal cancer to reduce toxicity, including neutropenia, while maintaining survival outcomes compared to the 28-day schedule.
What it foundThe 14-day trifluridine-tipiracil plus bevacizumab schedule showed non-inferior overall survival (HR 0.93, 95% CI 0.80-1.08) compared to the 28-day schedule, with median survival of 11.3 vs 10.3 months.
ContextThis confirms the 14-day schedule as a viable alternative to the conventional 28-day regimen, addressing toxicity concerns without compromising survival.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Sakakida T … PRABITAS investigators · The Lancet · IF 98.4 · PubMed ↗Permalink
Colorectalprospective cohort · n=320 · Oct 20, 2026 · J Gastroenterology · IF 5.7
New evidencerectal cancercolorectal surgeryepidemiologybiomarker
Clinical takeawayCounsel patients preoperatively about the risk of permanent stoma, particularly if they have ASA-PS ≥2, advanced clinical stage, or low serum albumin (<3.5 g/dL).
What it found6.9% of diverting loop ileostomies were not closed within 1 year; patients with non-closure more often had ASA-PS 2 or higher (86.4% vs 63.8%), stage III-IV disease (68.2% vs 38.9%) and albumin below 3.5 g/dL (31.8% vs 7.4%) than those closed.
ContextConfirms known risk factors for stoma non-closure and provides specific rates for preoperative counseling.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Miyo M … Clinical Study Group of The University of Osaka, Colorectal Group (CSGO-CG) · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
Colorectalrct · n=52 · Oct 23, 2026 · Nature Medicine · IF 52.5
Clinical takeawayNo clinical action yet: this is a phase 1/2 trial evaluating a novel T cell agonist in ICB-resistant solid tumors. Further phase 2 data are needed before considering clinical use.
What it foundInvikafusp alfa achieved a 14.8% overall objective response rate (4/27) at optimal biological doses (0.08 and 0.12 mg/kg) in ICB-resistant solid tumors, including partial responses in MSS CRC and PD-L1-negative NSCLC.
ContextThis study introduces a first-in-class bispecific T cell agonist targeting Vβ6/Vβ10 subsets, showing preliminary efficacy in ICB-resistant tumors, a population with limited treatment options.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Sullivan RJ … Gulley JL · Nature Medicine · IF 52.5 · PubMed ↗Permalink
Colorectalsystematic review · Oct 21, 2026 · J Clin Gastro · IF 2.9
Clinical takeawayNo clinical action yet: this is an epidemiological analysis of global trends and risk factors, not a study of interventions or diagnostics.
What it foundGlobal early-onset gastric cancer age-standardized incidence, death, and DALY rates declined annually by 2.13%, 2.80%, and 2.78% from 1990 to 2021.
ContextConfirms declining trends in early-onset gastric cancer globally but highlights persistent disparities across regions, genders, and socioeconomic indices.
No standard claimed for this paper
Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.
Cui X … Ning S · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink